Moving Beyond G-CSF Mobilization-Learning From a 15-Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma.

ABSTRACT:

Background

Stem-cell mobilization in multiple myeloma is usually done with G-CSF with or without Cyclophosphamide (Cy) based chemotherapy/Plerixafor. Pre-clinical data suggest the role of proteasome inhibitors in mobilization. We previously reported that Bortezomib (Bort) when added to a Cy-based regimen had a better stem-cell yield. Consequent to favorable results with Bort + Cy-G-CSF, we used Bortezomib with G-CSF too. Hence, four different mobilization regimens were used-Bort + G-CSF (Group-1); G-CSF + Plerixafor (Group-2); Bort - Cy-G-CSF (Group-3); Cy + G-CSF (Group-4). We report here our 15-year retrospective analysis of these 4 mobilization regimens.

Objectives

Primary objective was to determine proportion of patients with CD34⁺ dose ≥ 5 × 10⁶/kg

SUBMITTER: Mirgh S 

PROVIDER: S-EPMC12264575 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature